OREX : Analysis & Opinions

  1. Orexigen's Rocky Partnership Could End in Disaster

    May 29, 2015
    Market optimism was at all-time highs when Takeda Pharmaceuticals (NASDAQOTH: TKPYY) inked its collaboration deal with Orexigen ...
  2. 5 Key Takeaways From Orexigen's Earnings

    May 14, 2015
    The first quarter was a busy one for Orexigen Therapeutics (NASDAQ: OREX). The quarter marked the first full quarter of ...
  3. Orexigen Earnings Preview: 5 Things to Look For

    May 6, 2015
    Investors assumed that the market would rush to embrace drugs that could help reduce weight in obese patients. However, ...
  4. Should Orexigen Fear This Upstart?

    April 20, 2015
    Since obesity can lead to costly life-threatening conditions such as diabetes, heart disease, and even cancer, drugmakers ...
  5. Is Orexigen's Future Getting Brighter?

    April 1, 2015
    Orexigen Therapeutics (NASDAQ: OREX) was on the hot seat last month following the release of interim results from an ongoing ...
  6. Can Orexigen Win Where Obesity-Drug Rivals Failed?

    March 18, 2015
    For years, the prospect of new anti-obesity drugs coming to market captured the attention of medical professionals, potential ...
  7. Did Orexigen Make A Big Mistake?

    March 9, 2015
    Developing drugs isn't cheap. Drugmakers spend $1.4 billion in direct costs to bring a typical drug through research trials ...
  8. What’s The Drug That Will Finally Fight Obesity?

    March 4, 2015
    Orexigen just pulled back the curtain on interim results for a cardiac study that could catapult the company's Contrave obesity ...
  9. What Are The Real Economic Costs Of Obesity?

    March 2, 2015
    According to the Centers for Disease Control and Prevention, more than one-third of Americans are considered obese. Another ...
  10. Arena Pharmaceuticals – One Huge Step Forward, But Many More ...

    June 28, 2012
    ARNA shareholders got some major validation on June 27, 2012, when the company announced that the FDA had formally approved ...
  11. Wall Street Isn't Buying The Medifast Story

    March 5, 2012
    Medifast gets a lot of doubt on the Street.
  12. Arena's New Data Doesn't Change Obesity Pill Outlook

    May 30, 2011
    Arena's new data isn't new and doesn't address the company's biggest issues.
  13. FDA's Bizarro World - Orexigen Gets Panel Approval!

    December 8, 2010
    In a surprise decision, an FDA panel votes to approve Contrave, Orexigen's new obesity drug.
  14. FDA To Obesity Drugs: Drop Dead

    September 20, 2010
    An FDA panel knocks down yet another would-be obesity drug.
  15. Can Investors Fatten Up On Weight Loss?

    June 22, 2010
    Obesity is described as a multi-billion dollar crisis in North America, but how can investors profit from the solutions?
  16. Five Must-Ask Questions Before Taking The IPO Bait

    May 16, 2008
    IPOs often make great discussion but lousy investments. Learn how to avoid getting burned.
Trading Center